FEEDHealthcare · Medical Devices

FEED Stock Forecast: ENvue Medical, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$3.58

+0.28% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$3.3M

Ticker Nerd rank

23 / 100

Median analyst target

—

Analysts covering

—

Revenue$239K−51.6% y/y

Operating income−$5.5M

Net income−$4.9M

Free cash flow−$2.7M

Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−6.5%

−25.0%

YTD

−87.1%

−95.2%

From 52W high

−97.2%

From 52W low

+0.3%

$128

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

FEED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ENvue Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Issuance

Volatility

Revisions

Momentum

Quality

Value

Size (98): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FEED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FEED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FEED appears on the weeks it earns a place.

Performance

FEED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, ENvue Medical, Inc. returned −95.2% against +17.5% for the S&P 500, dividends included.

FEED vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FEED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

ENvue Medical, Inc. (FEED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.1×
Price / sales: 1.7×
Price / book: 0.1×
EV / EBITDA: −0.3×

Growth & margins

Revenue growth (YoY): −51.6%
Earnings growth (YoY): −51.6%
Gross margin: −111.3%
Operating margin: −2290.4%
Net margin: 6.0%

Returns & dividend

Return on equity: −59.1%
Return on assets: −21.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ENvue Medical, Inc. (FEED) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

ENvue Medical, Inc. has a market value of $3.3M and an enterprise value of $3.5M.
Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter shrank 51.6% year on year.
Net income over the same four quarters: −$21.1M, a −1093.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$11.7M.
ENvue Medical, Inc. spent $8.0M on share buybacks in the twelve months to 30 June 2026.
Shares outstanding: 8.2M.
Trailing P/E: −0.1×.
ENvue Medical, Inc. employs 12 people — $161K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

FEED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
FEEDENvue Medical, Inc.	$3.3M	23
VTAKCatheter Precision, Inc.	$3.3M	26
XAIRBeyond Air, Inc.	$3.1M	37
VVOSVivos Therapeutics, Inc.	$3.7M	32
NUWENuwellis, Inc.	$2.8M	15
NXLNexalin Technology, Inc.	$4.0M	25
BJDXBluejay Diagnostics, Inc.	$4.0M	20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ENvue Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FEED news & analysis

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

GlobeNewsWire · 9 Sept 2026positive

ENvue Medical announced it has resumed U.S. commercial shipments of its PainShield® device, which is manufactured in the United States, and has begun fulfilling open orders from its exclusive U.S. distribution partner, Ultra Pain Products, Inc.

Why it matters — FEED watchers would care because resuming U.S. commercial shipments and fulfilling distributor orders signals renewed product availability through the company's exclusive U.S. distribution channel.

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

GlobeNewsWire · 2 Sept 2026positive

ENvue Medical announced it has been selected to exhibit its ENvue Navigation Platform, a minimally invasive electromagnetic navigation system for guiding feeding tube placement, at the Vizient Innovative Technology Exchange.

Why it matters — Selection to exhibit at a Vizient event may raise visibility for ENvue's platform among healthcare providers and potential customers.

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

GlobeNewsWire · 18 Aug 2026positive

ENvue Medical announced an exclusive multi-year distribution agreement with Peak Medical for its UroShield product, expanding commercialization across the United Kingdom and Republic of Ireland. The agreement includes minimum purchase commitments of approximately $2.6 million.

Why it matters — This agreement extends ENvue's UroShield market reach into new territories and secures a committed revenue baseline through the minimum purchase obligations.

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

GlobeNewsWire · 12 Aug 2026positive

ENvue Medical, Inc. announced it has entered into a securities purchase agreement (an equity line of credit) with an institutional investor, providing access to an equity financing facility of up to $50 million, subject to the agreement's terms and conditions and stockholder approval. The company stated the capital is intended to support commercial growth, technology expansion, and strategic acquisitions.

Why it matters — FEED watchers would care because this facility gives the company potential access to up to $50 million in capital to fund growth initiatives, though it is contingent on stockholder approval.

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

GlobeNewsWire · 4 Aug 2026positive

ENvue Medical announced it has completed moving NanoVibronix manufacturing from Israel to the United States and consolidated its research and development operations in Tel Aviv, Israel. The company stated the moves support its broader initiative to reduce operating expenses and improve its cost structure.

Why it matters — A FEED watcher would care because the company describes the manufacturing relocation and R&D consolidation as a major strategic operational initiative aimed at reducing costs and improving efficiency.

FAQ

Frequently asked questions about FEED stock

How does Ticker Nerd's model rank FEED?

As at 12 Sept 2026, ENvue Medical, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the FEED stock forecast for 2030?

No analyst covering ENvue Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FEED are extrapolating price history, which says nothing about the business.

How has FEED stock performed over the past year?

ENvue Medical, Inc. returned -95.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ENvue Medical, Inc. do?

What is the latest news on FEED?

The most recent item we track (GlobeNewsWire, 9 Sept 2026): "ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders". ENvue Medical announced it has resumed U.S. commercial shipments of its PainShield® device, which is manufactured in the United States, and has begun fulfilling open orders from its exclusive U.S. distribution partner, Ultra Pain Products, Inc.

Company

About ENvue Medical, Inc.

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.

CEO Dr. Doron Robert Besser M.D. · 12 employees · United States · https://envuemed.com